Hematopoietic SCT (HSCT) and high-dose chemotherapy are being explored as therapy for various human refractory immune-mediated conditions, including inflammatory bowel diseases (IBD). Nevertheless, the exact immunological mechanisms by which the BM cells (BMCs) or immunosuppression provide remission from these diseases is not yet clear. In this work, we investigated the role of these therapies in the modulation of gut mucosal inflammation in an experimental model of IBD. Colitis was induced in mice by 2,4,6-trinitrobenzenesulfonic acid and after CY was administered (200 mg/kg) alone (CY group) or followed by BMCs infusion (HSCT group). Animals were followed for 60 days. Both HSCT and CY reduced the histopathological features of colitis significantly. Infused cells were localized in the gut, and a marked decrease of CD4 þ leukocytes in the inflammatory infiltrate on days þ 7 and þ 14 and of CD8 þ cells on day þ 7 was found in both treatments allied to impressive reduction of proinflammatory Th1 and Th17 cytokines. Although chemotherapy alone was the best treatment regarding the induction of immunosuppressive molecules, only HSCT resulted in increased survival rates compared with the control group. Our findings indicate that highdose CY followed by HSCT is effective in the modulation of mucosal immunity and in accelerating immune reconstitution after BMT, thus providing valuable tools to support the development and understanding of novel therapeutic strategies for IBD.
Introduction
Inflammatory bowel diseases (IBD) are chronic and relapsing disorders of the gastrointestinal tract resulting in diarrhea, abdominal pain, rectal bleeding and malnutrition.
1,2 IBD results from a complex series of interactions among susceptibility genes; the environment and both autoimmune and immune-mediated phenomena seem to be involved. 3, 4 Pathogenic bacteria or disruptions in the epithelial barrier activate DCs that trigger effector CD4 þ and CD8 þ T lymphocytes 5 together with increased production of cytokines such as IL-1, TNF-a, IFN-g, IL-12, IL-6 and IL-18. 6 In Crohn's disease, a bias toward the production of Th1 cytokines is observed, and recent data have implicated Th17 cells as having a key role in the intestinal inflammation. 5, 7 Although current therapies are aimed at various elements of the immunoinflammatory cascade, no drug is, at present, curative, and a significant percentage of patients is refractory or intolerant to many pharmacological approaches and requires repeated surgery to combat complications of the disease. 8, 9 Hematopoietic SCT (HSCT) for treatment of severe autoimmune diseases is being explored as therapy for various immune-mediated diseases, 10, 11 as well as the utilization of high-dose chemotherapy without stem cell rescue. [12] [13] [14] [15] Nevertheless, the exact immunological mechanisms by which BM cells (BMCs) or high-dose immunosuppression provide remission for those diseases, including IBD, is not yet clear. [16] [17] [18] [19] [20] Moreover, the success of patient trials depends largely on the elucidation of the cellular mechanisms involved in the pathogenesis and outcome of the disease after HSCT, which are not fully provided by the studies with human subjects, but can be achieved with animal studies.
The induction of colitis using the haptenizing agent TNBS (2,4,6-trinitrobenzenesulfonic acid) is commonly used, as it resembles Crohn's disease by inducing intestinal inflammation accompanied by the production of cytokines such as IFN-g, TNF-a and IL-12. 21 Accordingly, in this work, our aim was to investigate the role of high-dose chemotherapy and syngenic HSCT in the treatment of intestinal inflammation and in the modulation of gut mucosal immunity in acute TNBS-induced colitis with a long-term follow-up of the disease outcome.
Methods

Experimental animals
Colitis was induced in 6 to 8-week-old female Balb/c (recipient) mice, whereas male wild-type animals were the donors of BMCs. Mice were maintained in micro isolator cages in temperature-controlled rooms with sterile food and water ad libitum, in the animal housing facility of the Department of Biochemistry and Immunology, University of Sa˜o Paulo, Ribeira˜o Preto, Brazil. Mice were divided into four groups (eight animals per group): the PBS group and Colitis group received intra-rectal infusion of PBS and TNBS, respectively, and the Colitis þ CY group and Colitis þ CY þ BMC group, submitted to same protocol of colitis induction followed by CY infusion alone and CY followed by BMC infusion, respectively. All experiments were performed in accordance with the protocols approved by the School of Medicine of Ribeira˜o Preto Institutional Animal Care and Use Committee.
Induction of experimental colitis
For colitis induction, TNBS (Sigma-Aldrich, Deisenhofen, Germany) was used in 50% ethanol and administered (175 mg/kg) to anesthetized mice (2.5%tribromoethanol) through a 3.5-F catheter carefully inserted into the rectum. The catheter tip was inserted 4 cm proximal to the anal verge and to ensure distribution of TNBS (100 ml) mice were held in a vertical position for 1 min after the enema. 22 Controls were administered PBS alone using the same technique.
CY chemotherapy and syngenic BMT As the autologous BM collection requires surgical intervention and to avoid the consequent animal suffering, we performed the experiments with BM harvested from isogenic mice with exactly the same lineage as the recipients. The marrow obtained in this way was termed syngenic. [23] [24] [25] For immunosuppression, CY (Enduxan; Roche, Basel, Switzerland) was administered to female Balb/c mice (200 mg/kg), by i.p. injection, 24 h after colitis induction. Donor BMCs were collected by flushing the bone shafts of the femurs and tibias with sterile cold PBS, followed by staining with 5 mmol/l carboxyfluorescein diacetate succinimidylester (CFSE). Then, 24 h after CY infusion, 1.5 Â 10 7 male BMCs stained with CFSE and 100 ml of medium were infused in Colitis þ CY þ BMC group and Colitis þ CY group, respectively, by retroorbital plexus venous injection. The day of the CY injection was designated as day 1. No antibiotics were used as prophylaxis or treatment for opportunistic infections in the transplant recovery period, because there is extensive evidence that experimental colitis is attenuated when animals are treated with antibiotics. 26, 27 Global leukocyte counts were performed daily in a Neubauer chamber from the fifth day until the sixteenth day after BMC infusion to assess immune reconstitution in transplanted mice.
Measurements and sample processing Measurement of body weight was assessed daily and the survival rates were determined in independent groups of animals. On days 7, 14 and 60, recipient mice were killed. The colon was removed, opened longitudinally and divided into four parts: one was frozen for cytokine assay; the second part was embedded into preservative freezing medium (Tissue-Tek OCT Compound, Miles, Elkhart, IN, USA) for immunohistochemistry/fluorescence analysis; the third part was fixed in 10% formalin for paraffin inclusion; and the fourth segment was used for DNA extraction. In addition, BMCs were collected by flushing the bone shafts of the femurs and tibias of recipient mice and used for DNA extraction and detection of the Y-chromosome by PCR assay, as in the colon segments described above.
DNA extraction and PCR
The BMCs were centrifuged (5 min, 500 Â g) and erythrocytes were lysed. Then, BMCs or colonic tissue samples were homogenized in PBS and digested in a lysing buffer (Tris-HCl (pH8.5), 50 mM; EDTA, 1 mM; Tween 20, 0.5%; proteinase K, 0.2 mg/ml) at 56 1C for 1 h, followed by enzyme inactivation at 95 1C for 10 min and RNAse treatment of the samples (10 mg/ml) at 37 1C for 1 h. Subsequently, DNA was extracted by standard protocols with phenol-chloroform, as described previously. 28 To perform the PCR, the primers used were ymt- 
Histopathological analysis and morphometry
Tissue samples embedded in paraffin were sectioned (5 mm) and stained with hematoxylin-eosin. The images were captured in a common optic microscope connected to a digital camera and analyzed using an image analysis system (ImageTool 2.0 software-University of Texas Health Science Center, San Antonio, TX, USA). For each collected sample, 10 fields of 100 mm 2 were analyzed to determine the area occupied by inflammatory cells (magnification, Â 40). For goblet cell counts, an area equivalent to 20 colonic crypts in each animal was evaluated.
Confocal microscopy
Frozen colonic sections (5 mm) were fixed, stained with 4,6-diamidine-2-phenylindole dihydrochloride (DAPI, blue fluorescence; Molecular Probes, Carlsbad, CA, USA) and analyzed in a confocal microscope (TCS SP2, Leica Microsystems, Bannockburn, USA) to identify CFSE þ cells in the gut of transplanted animals.
Immunohistochemical detection of CD4, CD8 and MAC-1
To detect CD4, CD8 or MAC-1 (CD11b)-positive cells, 5mm frozen colon sections were fixed with acetone for 10 min. The slides were placed in a wet chamber and the endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 30 min, followed by incubation with PBS plus 3% (P/V) nonfat milk (Nestle´, Sa˜o Paulo, Brazil). The slides were washed with PBS and incubated overnight with rat IgG anti-mouse CD4 or MAC-1 antibodies (Abs) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rat IgG anti-mouse CD8 biotin-labeled Abs (Caltag Laboratories, Burlingame, CA, USA) or normal rat IgG (controls) diluted 100 times in PBS. After successive rinsing with PBS, the sections were incubated for 30 min with biotin-labeled goat anti-rat Ab (Santa Cruz Biotechnology) and washed three times in PBS. Next, the sections were incubated with avidin-biotin-peroxidase complex (ABC kit, PK-4000; Vector Laboratories, Burlingame, Canada), for 30 min at 37 1C and the brown-staining signal was generated with 3,3 0 -diaminobenzidine (Vector Laboratories). The slides were counterstained with Mayer's hematoxylin and the positive cells were counted in 10 fields of 250 mm 2 (magnification, Â 40), using the image analysis system ImageTool 2.0 software.
Cytokine determination
The cytokine concentrations were determined by sandwich ELISA. Colon samples were homogenized on ice-cold PBS containing protease inhibitor cocktail (Complete; Roche Applied Science, IN, Indianapolis, USA). The homogenates were centrifuged at 300 Â g at 4 1C for 10 min and the supernatant was used for ELISA. The cytokines IL-12p70, IFN-g, IL-10 and TGF-b (OpTEIA; BD Bioscience, San Diego, CA, USA) and TNF-a, IL-4, IL-6, IL-1b and IL-17 (Duoset; R&DSystems, Minneapolis, MN, USA) were assayed according to the manufacturer's instructions. The concentrations were calculated from a standard curve of murine recombinant cytokines. The OD was read at l ¼ 450 nm in a microplate ELISA reader (EMAX; Molecular Devices, Sunnyvale, USA) and the results were expressed as picograms of cytokine per 100 milligram of colonic tissue.
Statistical analysis
Results were expressed as mean ± s.e.m. and are representative of three different experiments. Statistical analysis was performed using analysis of variance (ANOVA) followed by Tukey post test. The log-rank test was used to analyze the survival curve. Po0.05 was considered statistically significant.
Results
High-dose CY with or without stem cell rescue reduces clinical disease activity in murine colitis First, to verify whether BM transplantation was related to any change in the clinical parameters of disease severity, the body weight and mortality rate were evaluated in transplanted and control animals. Results showed a decrease in body weight and increased mortality in Colitis mice when compared with the PBS group (Figures 1a and b) . Both Colitis þ CY and Colitis þ CY þ BMC groups improved significantly in body weight compared with the Colitis group (Figure 1a , Po0.05) and achieved similar weight gain to the PBS group, especially on day 60 after CY and BMC (Colitis þ CY þ BMC) or medium alone (Colitis þ CY) infusion. Moreover, CY followed by BMC infusion resulted in an increased survival rate in comparison with the Colitis group (Figure 1b) . However, the mortality rate was higher in mice that received CY alone (Colitis þ CY) compared with both Colitis and Colitis þ CY þ BMC groups (Figure 1b , Po0.05). The Colitis þ CY þ BMC animals also had faster leukocyte recovery (14 ± 1 days) compared with the Colitis þ CY group (7 ± 2 days).
Evidences of BMC homing
To evaluate whether the injected cells repopulated recipient's BM and reached the inflamed gut, samples of colonic tissue and BMC were collected from the recipient mice on days 7, 14 and 60 after colitis induction and transplantation, for detection of Y-chromosome. As visualized in Figure 2a , the Y sequence was detected at all the times analyzed in both gut and BM samples. Then, we next asked whether these cells were not only circulating cells but could also migrate toward the intestinal mucosa. Accordingly, we found CFSE þ BMCs in the tissue, especially within the inflammatory infiltrate of colon samples at all the times evaluated, even 2 months after transplantation, as confirmed by confocal microscopy (Figure 2b ). High-dose CY and syngenic BM transplantation equally reduce morphological signs of experimental colitis As transplanted BMC migrated to the inflamed gut, we next investigated their influence and the effects of high-dose CY in the control of the morphological changes induced by TNBS enema. As expected, TNBS-induced colitis manifested as patchy lesions in the colon. Affected areas showed an acute transmural disease with inflammatory cell infiltration, edema, ulceration, epithelial cell necrosis and loss of colonic crypts and goblet cells (Figure 3a) . Both Colitis þ CY and Colitis þ CY þ BMC groups equally showed significantly fewer inflammatory cells in the colons at all the times analyzed compared with the Colitis group. Actually, CY alone, or followed by BMT, completely abrogated the TNBS-induced inflammation and restored the normal histological appearance of the colon as soon as 7 days and as long as 60 days after immunosuppression and BMT (Figures 3a and b , Po0.05). CY also reestablished the goblet cell counts in both groups on days 7 and 14 ( Figures 3a and c, Po0 .05), and no difference was observed between both the treated groups (Figures 3a and b, P40 .05).
High-dose CY and syngenic BM transplantation specifically reduce CD4 and CD8 accumulation in the inflamed colon To differentially characterize the cellular infiltrate affected by immunosuppression and BMT in inflamed colon, frozen tissues were stained for CD4, CD8 or macrophage (MAC-1 þ ) surface markers. Results showed increased accumulation of leukocytes in the gut of the mice in the Colitis group when compared with controls (PBS group), and the infiltrate was composed mainly of CD4 þ and CD8 þ lymphocytes, suggesting their involvement in the pathogenesis of the disease (Figures 4a-d Once more, no difference in CD4 or CD8 cell counts was found between the treated mice (P40.05). We could not observe any relevant difference in the proportion of macrophages among all groups analyzed (data not shown).
Immunosuppression and syngenic BMT modulate cytokine interplay in the inflamed gut To understand how gut mucosal immunity was modulated after treatments, we further investigated the involvement of cytokines in the improvement of the intestinal inflammation. As shown in Figure 5 , Colitis mice exhibited higher levels of the cytokines TNF-a (Figure 5a ), IFN-g (Figure 5b ), IL-1b (Figure 5c ), IL-12p70 (Figure 5d ) and IL-17 ( Figure 5e ) than PBS group at all the times analyzed, in accordance with previous description of this colitis model. In addition, we observed a statistically significant decrease in TNF-a, IFN-g and IL-17 in the colon of mice treated with CY alone and with CY followed by autologous BMCs when compared with the Colitis group on days 7 and 14. On day 60, this difference was only statistically significant in TNF-a, IFN-g, IL12p70 and IL-17 levels between Colitis vs Colitis þ CY þ BMT group and IL1-b and IL-17 levels in Colitis vs Colitis þ CY (Po0.05) group. We could not detect any difference in IL-6 levels between colitis and both treated groups analyzed at any time point (data not shown). Then, to determine the possible involvement of regulatory molecules in the control of the inflammation, we assayed the expression of IL-10 and TGF-b. Interestingly, the results showed that colitis and both treated groups presented increased expression of TGF-b levels at all times analyzed when compared with controls (PBS group), with the exception of mice treated with CY followed by BMT, which showed a significant decrease in TGF-b levels when compared with the Colitis group on day 60 (Figure 5f , Po0.05). In contrast, IL-10 levels were found to be lower than those in control mice, in Colitis and in Colitis þ CY þ BMT groups at all the times, and statistically significant increases were found in Colitis þ CY mice on days 14 and 60 compared with the Colitis group (Figure 5g, Po0.05 ). In addition, we also investigated the levels of Th2 cytokine IL-4, important for counteracting the effects of Th1 responses. Surprisingly, all groups presented low IL-4 levels on days 7 and 14 when compared with controls, and on day 60, we found a tendency toward the normalization of this cytokine to control levels, except for Colitis þ CY þ BMT mice. In these animals, although the IL-4 levels were higher than at the previous times evaluated, a significant reduction in this cytokine was maintained, when compared especially with the Colitis group (Figure 5h , Po0.05).
Discussion
Hematopoietic SCT has been successfully employed in the treatment of many autoimmune diseases since the late 1990s. These clinical trials are based on extensive preclinical animal experiments in which autoimmune diseases may be cured by pseudoautologous or syngenic HSCT. 29 In addition, high-dose CY, usually used before HSCT, is also a chemotherapy treatment option for severe, refractory and immune-mediated illnesses. Accordingly, in the present study, our objective was to evaluate the potential therapeutic role of immunosuppression followed or not by syngenic BMT in experimental colitis, and the results show that both treatments were effective in reducing the clinical and the pathological features of the disease.
The exact mechanism of action of CY and HSCT in autoimmune disorders is not fully understood. The rationale of these therapeutic approaches is to eradicate pathogenic cells responsible for the disease development while sparing the pluripotent blood stem cells from any ill effect and immune reset, that is, to generate new selftolerant lymphocytes after chemotherapy elimination of self or auto-reactive lymphocytes. 11, 30 Despite the previous knowledge concerning the effects of chemotherapy and HSCT, the role of BM-derived cells in the intestine after transplantation is presently unclear. Both in animal models as well as in patients, it seems that BMCs are involved in the healing process after intestinal injury. 20, [31] [32] [33] [34] In our work, we detected BM-transplanted cells in the intestine, suggesting that another effect, rather than immunosuppression, may also contribute to regeneration or modulation of the local inflammatory response, as cytokine interplay was somewhat different between both treated groups. In accordance, biopsy specimens from the gastrointestinal tract of women who had received male BM transplants presented donor-derived epithelial cells in every part of the gastrointestinal tract. 35 The lower risks associated with HSCT beyond possible involvement of BMCs in the intestinal healing process justified a trial of this approach in patients with severe IBD. However, the therapy success depends on the elucidation of the cellular and humoral mechanisms of this approach. Then, to contribute to the elucidation of this process, we characterized the cellular infiltrate after high-dose chemotherapy and syngenic HSCT. The marked reduction found in CD4 and CD8 infiltrates in colon samples probably contributed to ameliorating the intestinal inflammation. In agreement, TNBS-induced colitis can be adoptively transferred in a cell dose-dependent manner into syngenic recipients by both CD4 þ and CD8 þ T lymphocyte subpopulations. 36 We next investigated the role of cytokines in modulating the mucosal immunity, and a central finding was the clear reduction of proinflammatory mediators after therapeutic CY and HSCT treatment, together with a prominent downregulation of Th1 cytokines. In addition to lowering Th1 prejudicial responses, treatment induced a dramatic reduction in IL-17 levels at all the times analyzed in both Colitis þ CY and Colitis þ CY þ BMC groups. The subset, Th17 cells, has emerged as an important mediator of the T-cell response in gut inflammation. IL-17 is a proinflammatory cytokine that enhances T-cell priming and stimulates fibroblasts, endothelial cells, macrophages and epithelial cells to produce multiple proinflammatory mediators such as IL-1, IL-6, TNF-a, NOS2, metalloproteases and chemokines. 7, 37, 38 On the contrary, the role of TGF-b in IBD is controversial. Although this cytokine acts on promoting immunosuppression and impeding the development of autoimmune conditions, TGF-b, together with IL-6, promotes the differentiation of pathogenic Th17 cells. 39, 40 Otherwise, concerning this and other classical antiinflammatory or Th2 cytokines such as IL-10 and IL-4, a significant increase in IL-10 was detected only in groups that received CY alone, suggesting that its production together with TGF-b, in the absence of inflammatory signals, probably lead to regulatory actions, thus inhibiting the incoming inflammatory responses in colitis mice treated only with CY. Surprisingly, TGF-b was increased in all groups, both diseased and treated, at all the time periods, except for 60 days after chemotherapy and BMC infusion. Moreover, at the same time, IL-4 reached normal levels in Colitis and Colitis þ CY mice in contrast to Colitis þ CY þ BMC group, which maintained diminished levels of this cytokine at the end of the evaluation period. These results suggested that chemotherapy alone is the best treatment with regard to the induction of immunosuppressive molecules and the switch to a Th2-protective profile in this colitis model. In addition, these data also highlighted the fact that the infusion of BMCs may also contain a few activated leukocytes that might be involved in a late response in our syngenic model, 41 although we did not observe any inflammation signals other than some cytokine production in this BMC-treated group. It is possible that such leukocytes may be responsible for keeping some factors, such as IL-1b, at low but similar levels to Colitis nontreated mice at the end of the period evaluated. Nevertheless, although not having a large production of regulatory or Th2 cytokines, the Colitis þ CY þ BMC mice showed remission of the inflammatory features of the Th1/Th17-mediated disease, with a relevant diminished mortality rate when compared with the chemotherapy group. Furthermore, as Colitis þ CY þ BMC mice also presented a shorter leucopenic period, it is possible that the graft did not contribute directly to the disease-improving effect, but rather seemed to be beneficial to accelerate leukocyte reconstitution and consequently decrease the infection risk and mortality in these animals.
Long-term remission of Crohn's disease in patients following BM transplantation for hematological disorders has been reported (reviewed by Leung et al. 16 ), and transplanted BMCs may re-establish normal immunological function by restoring T-cell function besides contributing to tissue repair. 11, 30 Therefore, these evidences suggest that SCT could be justified in some patients with IBD, which have already begun to be transplanted in some current trials, 42, 43 thus raising the question of whether the cell transplantation or the intense immunosuppression was the critical event for patient recovery. In our study, both therapeutic approaches induced remission of the disease and, although we did not elucidate the exact mechanisms of action of the graft in the treatment of the IBD, we showed that in this model, the infusion of the graft was extremely important to reduce mortality. In addition, as some clinical trials have already been performed with no description of the detailed mechanisms of the results obtained, 44, 45 the data presented here are relevant in showing some strong evidence of the mucosal immune system modulation after chemotherapy and/or HSCT for inflammatory intestinal disorders. Moreover, although we did not use an established chronic IBD model with repeated TNBS injections, which induces inflammatory responses that better resemble human Crohn's disease, 21 we still observed relevant alterations in gut mucosa 2 months after the induction of inflammation and mouse treatment, suggesting that the unique TNBS enema was enough for the evaluation of the long-term effects of immunosuppression and/or HSCT in this case. However, further studies will still be performed to evaluate the role of such treatments in classical IBD models that lead to disease development closer to human chronic Crohn's disease.
Finally, in addition to novel concepts that have recently been proposed to further explain the complicated mechanism of IBD, 46 we provided valuable tools to support the development and understanding of novel therapeutic strategies for this inflammatory disorder.
